Benzinga | Dec 7, 2020 03:30PM EST

UPDATE: Cowen On Exact Sciences Does Not See New House Bill On Multi-Cancer Screening As Likely To Move The Stock In the Near Term

New House Bill on Multi-Cancer Screening Unlikely to Move in Near-Term -Cowen Although the bill would likely benefit manufacturers of liquid biopsy cancer tests, we don't see a pathway until Cures 2.0 legislation, which will likely be combined with a bill to reauthorize FDA user fees in 2022.